ASGR1 Genotype

Your liver has a built-in cholesterol-clearing system that most people never think about, and a small fraction of the population is born with a version that works a little less aggressively. Counterintuitively, that softer version appears to be protective: it lowers cholesterol and cuts the risk of coronary artery disease.

ASGR1 (asialoglycoprotein receptor 1) genotype testing looks for inherited variants in this gene. The result is fixed for life and reflects a piece of cardiovascular risk that standard cholesterol panels can hint at but not explain.

What ASGR1 Actually Does

ASGR1 codes for one piece of a receptor on liver cells (the asialoglycoprotein receptor) that grabs certain sugar-coated proteins from the bloodstream and pulls them inside the liver to be broken down. It also plays a role in clearing aging platelets and other circulating proteins, helping keep blood composition in balance. Genetic variation in ASGR1 mainly affects how this receptor behaves, which in turn influences blood lipids.

When the receptor's activity is genetically dialed down, the liver shifts its handling of cholesterol-carrying particles. People who inherit a partially disabled copy end up with lower non-HDL cholesterol (the harmful fraction that includes LDL and other artery-clogging particles) and lower long-term cardiovascular risk.

Heart Disease Risk

This is where ASGR1 has the strongest human evidence. A rare 12-base-pair deletion in ASGR1 (called del12) activates a cryptic splice site, producing a shortened, unstable protein that is prone to degradation. People who inherit one copy carry meaningfully less working receptor than non-carriers.

In a large Icelandic study of roughly 119,000 people, heterozygous carriers of del12 (about 1 in 120 people studied) had non-HDL cholesterol that was 15.3 mg/dL lower than non-carriers in the imputed-genotype analysis (the directly genotyped analysis showed a 13.6 mg/dL reduction, 95% confidence interval 9.4 to 17.7), and their risk of coronary artery disease was 34% lower (95% confidence interval 21% to 45%). A second rare loss-of-function variant in ASGR1 (p.W158X, found in about 1 in 1,850 people) was also linked to lower non-HDL cholesterol.

More common ASGR1 variants point the same direction. When researchers combined common variants into a gene score, each 10 mg/dL drop in LDL cholesterol attributable to ASGR1 was associated with about 23% lower coronary artery disease risk (odds ratio 0.77, 95% confidence interval 0.62 to 0.96). That magnitude is similar to what is seen for genetic scores in HMGCR (the gene encoding the protein statins target), NPC1L1 (the protein ezetimibe blocks), PCSK9, and LDLR. The takeaway from this more recent analysis is that the heart-protective effect of common ASGR1 variants tracks closely with how much they lower LDL. This sits in some tension with the original Icelandic study, which suggested the del12 variant's protection against coronary artery disease was larger than what its cholesterol-lowering effect alone would predict. The question of whether ASGR1 offers extra benefit beyond LDL lowering is still being worked out.

Lifespan and Whole-Body Effects

A genetic analysis simulating the effect of an ASGR1-blocking drug found that the same genetic signal associated with lower LDL was also linked to a longer lifespan, roughly 3.3 additional years per standard-deviation drop in LDL cholesterol attributable to this pathway (95% confidence interval 1.0 to 5.6). The colocalization probability for this lifespan signal was modest (about 0.42 for lifespan and 0.30 for coronary artery disease), meaning the genetic effects on LDL and on these outcomes may not be driven by the exact same causal variant, an important caveat when interpreting the size of the benefit. The same analysis found lower apoB (a count of harmful cholesterol-carrying particles) and lower triglycerides. The original Icelandic study, which directly compared carriers to non-carriers rather than simulating drug effects, found a more modest 1.5-year survival advantage in del12 carriers.

The picture isn't entirely simple. The same genetic analysis found that simulated ASGR1 inhibition was linked to higher alkaline phosphatase and gamma glutamyltransferase (two liver enzymes), higher IGF-1 (a growth-related hormone), higher C-reactive protein (a general inflammation marker), lower albumin and calcium, and shifts in red blood cell traits. There were no clear links to gallstones, body fat, or type 2 diabetes. These shifts hint at modest systemic effects beyond cholesterol, but none have been shown to translate into harm in carriers, and overall mortality risk goes down.

Reconciling the Mixed Signals

It can look paradoxical that lower ASGR1 activity is tied to both lower heart disease risk and higher liver enzymes or inflammatory markers. The simpler way to read it: ASGR1 is a phenotype indicator, not a single good-number bad-number marker. Reduced activity shifts the liver's cholesterol handling in a way that clearly protects arteries over a lifetime, while producing small biochemical signatures elsewhere that, on current evidence, do not undo that protection. Carriers in large groups studied live longer and have less heart disease.

Blood Clotting and Platelets

Because ASGR1 helps clear sugar-coated proteins from circulation, it has been linked to coagulation factor VIII levels, consistent with its role in breaking down glycoproteins like von Willebrand factor and factor VIII. Carriers of del12 show changes in platelet surface sugar patterns, but platelet aggregation itself was no different from non-carriers, though that comparison came from a small sample (12 carriers and 10 controls). There is currently no human evidence that ASGR1 variants meaningfully change bleeding or clotting risk in carriers.

How This Compares to Standard Lipid Testing

A standard lipid panel shows what your cholesterol looks like today. It does not tell you whether you inherited a built-in advantage or disadvantage in clearing cholesterol particles. ASGR1 genotype is one piece of that inherited picture. Someone with mildly elevated LDL on a standard panel who also carries a protective ASGR1 variant likely has a different lifetime cardiovascular trajectory than someone with the same numbers but no protective variant, though this has not been directly demonstrated in a clinical outcomes study comparing matched individuals.

That said, the loss-of-function variants that drive the strongest effects are rare. Most people who get tested will not carry them, and the more common ASGR1 variants explain only a small portion of cardiovascular risk on their own. ASGR1 is best understood as one input into a broader risk picture that also includes apoB, lipoprotein(a), and other inherited lipid-related signals.

Your One-Time Result

This is a one-time test. Your ASGR1 genotype was set at conception and will not change. There is no need to retest your genotype unless your lab uses a method where the variant call confidence is in question, in which case a confirmatory test using a different technique can resolve it.

The value of knowing your ASGR1 status is not in retesting it. It is in using the result to inform how aggressively and how often you track the modifiable lipid and cardiovascular markers that respond to your choices: apoB, LDL cholesterol, lipoprotein(a), and overall cardiovascular risk over time. Get a baseline lipid and apoB panel, and recheck at least annually if you are actively managing your cardiovascular risk.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific ASGR1 variants it is designed to find. A result showing no risk or protective variant does not rule out rarer variants in the same gene that the panel does not test.
• Ancestry-specific frequencies: the del12 variant was originally identified at meaningful frequency in Icelandic and Northern European populations. Its frequency and clinical meaning may differ in other populations, and the broader applicability of these findings outside the studied groups is still being defined.
• Variants of uncertain significance: an unexpected ASGR1 variant may be reported with unclear clinical meaning. These calls are not actionable on their own and warrant discussion with a clinician familiar with genetic testing.
• Direct-to-consumer vs clinical-grade testing: some consumer reports cover only a handful of variants in ASGR1 and use lower-confidence methods than clinical laboratory sequencing. If a consumer test flags an ASGR1 variant, confirm it with a clinical-grade assay before acting on it.

What to Do With an Out-of-Pattern Result

If your test identifies a protective loss-of-function ASGR1 variant, the practical implication is not that you can ignore your cholesterol. It is that you have an inherited tailwind, and combining it with attention to the rest of your cardiovascular risk profile compounds the benefit. Pair the result with at minimum an apoB measurement, a lipoprotein(a) test (which is fixed for life and a separate inherited risk piece), and ongoing tracking of LDL and non-HDL cholesterol.

If you have a strong family history of premature coronary artery disease and your ASGR1 genotype is unremarkable, that does not rule in or rule out inherited risk. It just means ASGR1 is unlikely to be the answer. A broader workup including lipoprotein(a), an apoB-focused lipid panel, and consideration of monogenic familial hypercholesterolemia testing is the next step. A preventive cardiologist or lipidologist can help interpret the combination of findings, and a genetic counselor can be useful if multiple family members are affected. Because ASGR1 variants are inherited, biological children, siblings, and parents each have a 50% chance of carrying the same variant, and they may benefit from knowing as well.